We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Nanolock Sensor Detects Cancer Driver Mutation

By LabMedica International staff writers
Posted on 24 Jul 2017
Print article
Researchers have developed an accurate and sensitive “nanolock-nanopore” method that successfully diagnosed a known cancer driver mutation with results at the level of single DNA molecules in tumor tissues of thyroid cancer patients. The method can be adapted to detect a broad spectrum of both transversion and transition mutations, with applications from early diagnostics to individualized targeted therapy and monitoring.

Cancer driver mutations assist in the initiation and progression of cancers, many of which can be stopped in time if caught early enough. The current method for detecting driver mutations is real-time PCR, but it is not accurate enough to detect these genetic changes reliably. Researchers have developed methods to read the genetic sequence by moving it through a nanopore, but also this method is not accurate enough on its own.

Building on their previous work, Prof. Li-Qun Gu, of University of Missouri (Columbia, MO, USA), and colleagues sought a way to better pinpoint these mutations, and with single-molecule resolution. They developed and investigated their novel method using as a test case the known BRAF V600E mutation. The team has now found that mutant DNA carrying a nanolock undergoes a unique type of unzipping when it moves through the nanopore. Detecting this activity resulted in a highly accurate and sensitive nanopore fingerprint for the BRAF mutation in the thyroid cancer patients’ tumor tissue samples.

The researchers anticipate the approach, once integrated with a miniature high-throughput device, could enable PCR-free detection of various disease-causing mutations for diagnosis and prognosis.

The study, by Wang Y et al, was published July 5, 2017, in the journal ACS Sensors.

Related Links:
University of Missouri

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Blood Gas and Chemistry Analysis System
Edan i500
New
Ultrasonic Cleaner
UC 300 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.